EMCDDA releases state-of-the-art review on drugs and driving
26 Jun 2014 11:44 AM
An estimated 28 000 lives are
lost on Europe’s roads every year and a further 1.34 million people are
injured (1). Many of these accidents and deaths are caused by drivers whose
performance is impaired by a psychoactive substance. Alcohol remains the number
one substance endangering lives on European roads, but use of drugs and
medicines behind the wheel, particularly when combined with alcohol, is a major
challenge for policymakers. In a new report out today, Drug use,
impaired driving and traffic accidents, the EU drugs
agency (EMCDDA) reviews the latest research in this field
(2).
‘Alcohol, especially in
high concentrations, must remain the principal focus of prevention
measures’, says the EMCDDA. But it calls for
combined drug and alcohol use by drivers to be addressed ‘more
intensively’, given its association with a ‘very high risk of a
traffic accident’. The report states: ‘Statistically, the use of
amphetamines, cannabis, benzodiazepines, heroin and cocaine is associated with
an increased risk of being involved in and/or being responsible for an
accident, and in many cases, this risk increases when the drug is combined with
another psychoactive substance, such as alcohol’.
Released ahead
of International day against drug abuse and illicit
trafficking (26 June), the report updates a literature review
published by the agency in 2008. The new edition includes the results of
the European Commission-funded DRUID
project (2006–11), which contributed key evidence to road
safety policy by mapping Europe’s drink- and drug-driving problem across
13 countries (3). Also examined are over 500 studies,
published in Europe and internationally up to 2013, with a greater emphasis
placed on meta-analyses and systematic reviews, which combine and summarise the
most recent findings. The research is split into two study types:
epidemiological (e.g. roadside surveys) and experimental (e.g. performance
tests).
The report reveals how cannabis
(THC) is the most frequently detected illicit drug in drivers (followed by
cocaine and amphetamines) and benzodiazepines the most frequently found
medicine. Large differences are observed among countries, with more alcohol and
illicit drugs found in southern Europe and more medicinal drugs in northern
Europe.
The report explores methodology,
prevalence and the effects of substances on performance. It concludes:
‘The chronic use of all illicit drugs is associated with some cognitive
and/or psychomotor impairment and can lead to a decrease in driving performance
even when the subject is no longer intoxicated’. Among concerns raised in
the report is the variety of drugs available today: ‘The range of
psychoactive substances available for illicit use is increasing, and recent
studies are finding evidence of their use among
drivers’.
EMCDDA Director Wolfgang
Götz says: ‘We are all aware of the link between
alcohol and road traffic accidents and this is reflected across Europe in a
robust policy response to the problem. Less well understood, and of growing
importance for future policy development, however, is how the use of other
psychoactive substances may affect driving performance. As drug consumption
patterns change, particular concerns arise. These include: an ever-expanding
range of psychoactive substances and medicinal products as well as
context-specific risks such as those posed by young people driving home from
nightlife venues after consuming a mix of alcohol and
drugs’.
Götz a
dds: ‘Today’s report provides a state-of-the-art review of the
growing evidence base on substance-impaired driving. I am convinced that it
will not only prove a timely, and much-needed, tool for understanding this
rapidly-evolving area, but also facilitate the development of more
comprehensive road safety policies’.
The prevention of driving under
the influence of drugs is one of the priorities outlined in the current EU
drugs action plan (2013–16).